Lawitz E, et al. - In participants with hepatitis C virus (HCV) genotype (GT) 1- 6 infection, researchers examined the two-drug combination of ruzasvir (RZR) 60 mg plus uprifosbuvir (UPR) 450 mg for effectiveness and safety when administered for 12 weeks. In this open-label clinical trial, they enrolled 160 participants including treatment-naive or -experienced and cirrhotic or noncirrhotic individuals with chronic HCV GT1-6 infection and provided them the above oral regimen once daily for 12 weeks. Participants with GT1a infection had SVR12 rates of 96% (52 of 54); in those with GT1b infection it was 100% (15 of 15); in those with GT2 infection it was 97% (28 of 29); in those with GT3 infection it was 77% (30 of 39); in those with GT4 infection it was 90% (18 of 20), and in those with GT6 infection it was 67% (2 of 3). While it was effective only for certain genotypes, participants were able to tolerate the combination of RZR 60 mg plus UPR 450 mg once daily for 12 weeks overall.